Have a personal or library account? Click to login
Sunitinib and Reversible Posterior Leukoencephalopathy Syndrome: the usual suspect but not always the culprit. A case report. Cover

Sunitinib and Reversible Posterior Leukoencephalopathy Syndrome: the usual suspect but not always the culprit. A case report.

Forum of Clinical Oncology
Volume 15 (2024): Issue 1 (December 2024)
By: Ourania Katopodis,  Maria Lerikou,  Georgios Karagiorgis and  Spyridon Arvanitakis  
Open Access
|Apr 2025

Authors

Ourania Katopodis

Department of Medical Oncology, Euroclinic of Athens, Athens, Greece

Maria Lerikou

Department of Medical Oncology, Euroclinic of Athens, Athens, Greece

Georgios Karagiorgis

Department of Neurology, Euroclinic of Athens, Athens, Greece

Spyridon Arvanitakis

sarvanitakis@doctors.net.uk

Department of Medical Oncology, Euroclinic of Athens, Athens, Greece
DOI: https://doi.org/10.2478/fco-2024-0002 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Journal RSS Feed
Language: English
Page range: 14 - 18
Submitted on: Jul 17, 2024
Accepted on: Nov 13, 2024
Published on: Apr 15, 2025
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Sunitinib,
Reversible Posterior Leukoencephalopathy Syndrome,
Renal cell carcinoma,
Hypertension,
Status Epilepticus
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology

© 2025 Ourania Katopodis, Maria Lerikou, Georgios Karagiorgis, Spyridon Arvanitakis, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 15 (2024): Issue 1 (December 2024)Next article